We are experienced and reliable partner for all entities seeking a trustworthy professional to delegate commercialization and investment process. We dedicate our services in particular to all inventors of innovative solutions, scientists, business angels, investment funds, technology transfer offices, business incubators, science and technology parks, technology companies as well as to companies and other organizations that actively participate in the process of commercialization of innovative solutions.
We look forward to working with you!
19.12.2018Shocking use of genome editing
The day before an international summit devoted to genome editing, He Jiankui – a Chinese researcher at Southern University of Science and Technology in Shenzen – has managed to shock many by claiming to have altered the genomes of twin sisters. The alteration was intended to make the child's cells resistant to infections by HIV.
04.12.2018Brain cells change their own DNA inducing Alzheimer's disease
Contrary to most cells present in our bodies, neurons located in the brain are capable of "shuffling" their own genes – such discovery was made by researchers in their landmark study. These changes may differentiate proteins present in the brain which, in turn, is conducive to the development of Alzheimer's disease.
26.11.2018Step closer to innovative pain reliever
The results of phase 3 prove that Pfizer and Eli Lilly have come a step closer to get tanzeumab – an antibody blocking the nerve growth factor (NGF) and an alternative to opioids applied to treat chronic pain – at the filing stage of trials.
15.11.2018Alcon and Philips to develop cataract surgery-supporting platform
Alcon, the Eye Care Division of Novartis, set itself the goal of developing a digital platform in cooperation with Philips. The aim of this joint initiative is to improve cataract surgery.
02.11.2018Genome editing method CRISPR to become more efficient
The CRISPR-Cas9 system has been extensively researched due to its potential therapeutic use. Unfortunately, limitations concerning the number of locations on the genome it may encompass still constitute its major weakness. Scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme which, in their view, may contribute ...
16.10.2018Getting closer to bone regenerative therapy
The power of the human bone in terms of healing itself is limited. Its capability for repairing fractures wanes along with age, while the cartilage of adults is almost impossible to undergo renewal. However, after 10 years of research, scientists at Stanford University have identified a human skeletal stem cell that can develop into bones, the ...
09.10.2018CRISPR method identifies gene fighting Zika virus
CRISPR – a gene editing system – is widely used as a tool for performing genome screenings. Scientists at Southwestern Medical Center University of Texas have provided information of their successful use of CRISPR to indicate a gene that helps human cells prevent themselves from being infected by flaviviruses like Zika.
28.09.2018Antibody combination controls HIV like drugs
Antiretroviral therapy (ART) is a conventional standard in the treatment of HIV.Unfortunately, patients need to take their drugs on a daily basis and it is hard to follow the routine throughout a lifelong battle like this.Researchers at Rockefeller University suggest that an aggregation of HIV antibodies may keep the virus under control for entire ...
13.09.2018For rescue of dogs with Duchenne muscular dystrophy (DMD)
Eric Olson, Ph.D., the founder of Exonics Therapeutics and director of Hamon Centre for Regenerative Science and Medicine UT Southwestern, has been working on the implementation of CRISPR gene editing for the treatment of Duchenne muscular dystrophy (DMD) for several years. He is a step closer in terms of reaching the goal now.
05.09.2018Onset of gene editing in humans
CRISPS Therapeutics and Vertex Pharmaceuticals are the first companies to conduct a human trial of the gene editing technology. The trial will be carried out in Germany, while the gene therapy itself will undergo testing in patients with beta-thalassemia.
24.08.2018Two proteins being promising for treatment of obesity
A new target for treating obesity – the MP-2 enzyme that is related to two proteins – is now undergoing clarification. It blocks the signalling of leptin which, under normal conditions, prevents people from consuming excessive amounts of food. The discovery has a great potential for successful commercialisation at a later time.
07.08.2018Problems to affect cultivation of CRISPR-modified plants
Hopes for a regulatory road for genetic engineering made easier in Europe's agricultural sector were dispelled by the Court of Justice of the European Union. In the closely followed case, the court declared that plants modified with new techniques for gene editing that exclude a transfer of genes between organisms (such as CRISPR) are to undergo ...
01.08.2018Reprogrammed stem cells to treat Parkinson's disease
Researchers from Japan have announced the commencement of a clinical trial for the treatment of Parkinson's disease with neurological material obtained from induced pluripotent stem cells (iPS).
16.07.2018Launch of first tests on speeded-up inheritance in animals
Scientists have used CRISPR (a tool for the genome editing) to influence the speed of inheritance of certain traits in animals. The method is known as "a gene drive".
09.07.2018Serotonin improves ability to learn
Serotonin mediates communication between nerve cells. It is commonly known as the hormone of happiness. Research published in Nature Communications demonstrate new properties of this compound.
29.06.2018Artificial Intelligence to help cure autism
Children suffering from autism spectrum disorder tend to find it difficult to recognise the emotional states of others. Robots that are able to demonstrate emotions and engage autistic children in various activities through AI and machine learning are getting more popular.
20.06.2018From cell to animal
Planaria sp. are barely larger than apple seeds, yet they have got unique regenerative capabilities that might be the envy of quite a few animals. It turns out that it is one protein that is responsible for the process. In the near future, it will be possible to make use of the discovery.
11.06.2018Surprising connection of nicotine with fat cells discovered
It has long been known for scientists engaged in a fight against obesity that white fat cells are "unhealthy", as they store tryglicerides and other harmful substances. Conversely, brown cells are desired due to the protection against an excessive increase in the body mass they provide and their capability for burning fatty acids. Now, ...
01.06.2018Curious antibodies discovered in sharks and camels
At the Institute of Marine and Environmental Technology of Inner Harbor in Baltimore, within the state of Maryland, blood is drawn from the caudal vein of sharks every couple of weeks. It is indispensable for further research, as it has turned out that the mini-antibodies it contains may lead to the development of medicines for cancer and many ...
09.05.2018Bacteria found way for effective intestinal colonisation
Antibodies constitute one of the most effective defensive mechanisms of the organism against pathogens. Still, one of these proteins facilitates the occurrence of permanent intestinal colonisation by certain bacteria – which also affects health.
27.04.2018Mitochondrial DNA plays a part in metastases
Recent experiments on mice have demonstrated that mitochondria – both as present within a cancerous tumor and outside of its structure – affect the spread of cancer in terms of catalysing or inhibiting the process. Everything depends on their origins.
03.04.2018CRISPR tool to become more precise from now on
While the genome editing method CRISPR is groundbreaking, it is unfortunately not yet perfect. It may lead to the emergence of mutations in random sites of the genome and is only applicable to a limited part of it. Various scientific groups are carrying out continuous research on improving the performance of this tool and everything seems to ...
20.03.2018What will the year 2018 bring to the science sector (Part II)?
Many factors will affect the development of science in 2018. Apart from the previously mentioned political questions, the finalisation of ongoing scientific research and exploration of space will also have crucial parts to play.
28.02.2018What will the year 2018 bring to the science sector (Part 1)?
It is certain that political changes are to clearly influence the development of science in the forthcoming year. This is due to decisions of a number of countries – both in the territory of Europe and the remaining parts of the world.
05.01.2018Faulty agricultural practice leads to food contamination with deadly toxin
It turns out that aflatoxin, an exceptionally dangerous toxin, may appear in cereals, corn, rice and nuts that are intended for consumption or processing due to faults committed during crop cultivation. This toxic substance is produced by a fungus named Aspergillus flavus and may cause stunted growth in children, liver cancer and, when consumed in ...
13.10.2017Nobel Prize for research on biological clock
Three scientists from the U.S. were awarded this year's Nobel Prize in Physiology or Medicine. The research concerned the synchronisation of the organism with the circadian rhythm on Earth.
20.07.2017Bees dying out due to pesticides
Europe’s largest field research on pesticides has proven that neonicotinoids – used for agricultural purposes – may be detrimental both to honey and wild bees. The monitoring has lasted for 2 years, encompassing 33 agricultural sites in the territories of Great Britain, Hungary and Germany.
05.07.2017Manipulation of DNA made even easier
A new tool has enabled scientists to perform the manipulation of genomic DNA of virtually any animal, proving to be exceptionally flexible and effective. The CRISPR system will serve the modification of gene expression in order to improve the understanding of the functions of genes.
06.06.2017Medicine to raise the dead
Belgian neuroscientists have made it possible for people affected by a condition identified as cerebral death to return to life. In order to achieve this, life function-restoring electrical impulses of 7-day efficiency that also recover one's brain activity have been applied.
09.05.2017Weapon against HIV at fingertips
The research results that explicitly demonstrate the presence of an already-existing method for halting the spread of HIV were published in Molecular Therapy scientific journal on May 3. All of that has been made possible thanks to the technology of genetic modification.
02.03.2017WHO publishes a list of bacteria dangerous to humanity
On February 27, WHO published a list of antibiotic-resistant pathogens that should be given the highest priority with regard to the discovery or invention of new drugs intended to combat them. There are 12 families of bacteria placed on the list as - according to WHO - posing the greatest threat to humanity.
09.11.2016Zombie invasion of Chicago to take two months to happen
The researchers of Argonne National Laboratory (ANL) have developed a computational model which makes them capable of predicting the rate at which diseases spread. In order to test the model, they asked themselves the question of how long would the transformation of the entire population of Chicago into zombies take.
05.09.2016"One Health" initiative
"One Health" initiative was first put forward at the beginning of the 21st century. Its name manages to summarise the concept that has been known for at least a century within two words only - namely, that both human and animal health are mutually dependent on each other, also being linked to the health status of entire ecosystems they ...
25.08.2016Not Only MERS Comes from Camels
There was a research work published in the August issue of reputable PNAS magazine, with its authors reporting that MERS-CoV is not the only zoonotic virus having its source in dromedary camels.
21.07.2016Blue Energy in the Nano Size
As reported by phys.org web page, As reported by phys.org web page, a team of researchers from Switzerland and the USA built a micro device generating electricity based on the osmosis phenomenon. The device is composed of a three-atoms-thick molybdenum membrane (molybdenum disulfide) and two water containers. One of the vessels contains fresh ...
13.07.2016Scientists have discovered how birds activate their ultraviolet vision
Certain species of birds, such as the chaffinch or sparrow, may also see ultraviolet light aside from their perception of visible light. Therefore, they are able to transmit information between each other in a way that is invisible to other species. Recent studies reveal ...
10.06.2016Promising research on therapeutic cancer vaccines
In the latest issue of "Nature" magazine group of Prof. Ugur Sahin published their promising results on therapeutic cancer vaccines. The researchers from German Johannes Gutenberg University in Mainz have developed a new ...
31.05.2016State of the World's Plants Report
Royal Botanic Gardens, Kew released in May its State of the World’s Plants Report. The study encompasses the assessment of current knowledge concerning the diversity of world’s plants, the description and assessment of hazards, as well as the evaluation of preventive attempts made to avoid them.
19.05.2016Left uncontrolled, weeds would destroy even a half of crop yields
Scientists from Weed Science Society of America and Kansas State University conducted a 7 years research regarding the weed influence on corn and soybeans yields in the U.S. and Canada. The study showed that if weeds were allowed to grow with no control measures, about half of corn and soybean crops would be lost.
25.04.2016Location data from two apps enables to identify the user
Scientists and engineers from Columbia University and Google identified a new threats for the web and mobile app users privacy. They have demonstrated that location-tagged posts on two social apps are enough to identify the user.
07.04.2016Squeezing a perovskite can improve its capabilities
Scientists from Stanford University discovered that squeezing the perovskite crystal can change its absorbance spectrum and increase the performance of solar cell made of perovskite material.
Researchers from the University of Illinois developed microscopic biological robots (bio-bots), composed of muscle cells and artificial skeleton printed on a 3D printer.
22.03.2016Adult brain is not hardwired
For many years it was believed that the possibilities of reorganization in the adult brain are negligible. However, more and more studies suggests that adult brain plasticity is surprisingly high and may even lead to the adoption of completely new functions by areas fulfilling usually another tasks.
14.03.2016Another (polish) step towards saving the bees
Researchers from the Department of Pharmacology and Toxicology of the National Veterinary Institute have identified a mixture of 57 kinds of pesticides and their metabolites in poisoned bees. A new method of detecting a range of pesticides can help solve the mystery of bee extinction process and contribute to the development of rescue methods.
22.02.2016Experimental therapy against blood cancer successful
Researchers from Fred Hutchinson Cancer Research Center in Seattle claim extraordinary success of experimental therapy using patient’s own engineered T-cells against blood cancer. Twenty- seven out of 29 patients with acute lymphoblastic leukemia (ALL) showed no trace of cancer in their bone marrow following the infusion.
12.02.2016Groundbreaking observation of gravitational waves
On September 14, 2015 at 09:50:45 UTC the two detectors of the Laser Interferometer Gravitational-Wave Observatory (LIGO) simultaneously observed a transient gravitational-wave signal generated by two merging black holes. Observation was made almost a century after Albert Einstein predicted the existence of gravitational waves.
02.02.2016The genetic origins of schizophrenia revealed
According to the article published on the www.medicalxpress.com website, a new study published in the January 27, 2016 issue of Nature revealed that the risk of schizophrenia can be increased if a person inherits particular structural form of gene related to complement component 4 (C4) protein.
22.01.2016New largest prime number found
On January 7th, the Great Internet Mersenne Prime Search (GIMPS) project announced the discovery of the new largest known prime number, having 22 338 618 digits. Dr. Curtis Cooper, a volunteer that participate in GIMPS program, used one of his university's computers to pinpoint a new prime.
18.01.2016New LED with luminescent proteins
According to Plataforma SINC scientists from Germany and Spain have developed a method of preparing a new biological LEDs (BioLEDs) based on the luminescent proteins placed in a polymer matrix. The obtained structure has a form of a rubber. Device emits white light using a blue or ultraviolet LED as a backlight and a combination of new luminescent ...
26.12.2018Treatment of osteoarthritis made easier with nanocarrier
A team of researchers at the Massachusetts Institute of Technology designed a material that could facilitate the deeper penetration of drugs into tissues generating the cartilage. The results of studies they conducted on animals are promising.
11.12.2018Step closer to new drug for schizophrenia
A schizophrenia drug by the Alkermes company has successfully completed phase 3 of trials, as a result of which it will be officially submitted for approval to FDA in mid-2019. It was observed that patients gained their weight at a slower pace with regard to olanzapine – the antipsychotic providing a basis for the new therapy.
19.11.2018Gilead pays USD 50 mln to cooperate with Tango Therapeutics startup
Gilead and Tango Therapeutics join forces in the immune-oncology sector. The agreement they conducted opens up a possibility for Gilead to acquire the worldwide rights to five inventions owned by Tango.
09.11.2018Cuts in Novartis
Jay Bradner has announced that Novartis has closed down one-fifth of its programs related to drugs. The cuts are meant to constrain the overly expanded volume of Novartis' pipeline and terminate therapies that do not conform to the current policy of the company.
22.10.2018FDA approves first stent in 17 years
FDA has given green light to a new stent type named PK Papyrus, created by Biotronik. It will be used in emergency cases – to treat perforations in the heart's blood vessels. It is the first approval of this kind in the "trifling" period of 17 years.
12.10.2018AstraZeneca has China-related plans
AstraZeneca is planning to improve the use of artificial intelligence, robots and digital applications so that the efficiency of disease treatment in China can be supported in terms of changes applied to it, along with improvements to be implemented to the functioning of healthcare services.
03.10.2018USD 80 million for new therapy
Morphic Therapeutic received USD 80 million for a new therapy. It concerns oral and small-molecule formulations related to receptors present in the cell surface. In case of failure, the therapy will be employed to the treatment of inflammations, fibroses or cardiometabolic diseases and tumours.
18.09.2018Is menopause over?
The KaNDy Therapeutics company has raised necessary funds to commence a phase 2b trial within the scope of its nonhormonal therapy for the symptoms of menopause. The company raised about USD 32 million.
07.09.2018New drug for epilepsy on its way
The Xenon company is performing clinical trials of its XEN1101 drug on humans. The product is expected to provide an opportunity for the treatment of epilepsy.
28.08.2018FDA approves world's first analgesic nerve stimulator
FDA authorised the placing on the market of a dual-lead device for peripheral nerve stimulation. It is SPR Therapeutics which is accountable for this discovery. The stimulator will provide a minimally invasive and non-opioid alternative aimed to deal with acute and chronic pain, both of post-operative and post-traumatic types.
15.08.2018New antibody therapy on its way
HiFiBiO Therapeutics has signed a deal with Japanese Big Pharma and its friend from the common sector, the Takeda company. Its goal is to develop antibody-based therapies for various gastrointestinal diseases, cancers and disorders of other types.
03.08.2018PTC spends USD 200 million on takeover of Agilis
PTC Therapeutics is paying USD 200 million for the acquisition of Agilis Biotherapeutics. This settlement provides PTC with ownership rights to a gene therapy for rare deficiency of AADC in a neurotransmitter-related disease.
20.07.2018Novartis acquires rights to innovative anti-inflammatory drug
Pharmaceutical giant Novartis is to spend USD 110 million for the purchase of the global rights to Galapagos and MorphoSys companies that are developing the anti-IL-17C (MOR106) antibody. The transaction will pave the way for Novartis to treat atopic dermatitis with the use of monoclonal antibodies.
09.07.2018FDA approves powerful antibiotic
Achaogen company has received the approval of Food and Drugs Administration (FDA) with regard to the marketing authorisation of its highly-efficient Zemdri antibiotic. It will be used when other medicines fail to succeed.
29.06.2018Mediocre effectiveness of modern flu vaccines
It turns out that cell-based flu vaccines are only slightly better in terms of effectiveness when compared to those of the previous generation. The opinion has been confirmed by the research conducted by FDA (Food and Drugs Administration).
20.06.2018Interesting therapy combines effectiveness with protection
CAR-T cell-based cancer treatment uses own lymphocytes of individual patients. Its goal is to elicit an immune reponse of one's organism against cancer, while there exists certain risk of that CAR-T cells might turn out to be too aggressive, making such treatment harmful to patients. However, a certain solution has been developed to deal with this ...
11.06.2018Hope for diabetics
A transplant of pancreatic cells may become the main type of treatment applied to the diabetics suffering from type 1 diabetes. However, there is one considerable problem related to it. The transplanted cells are reluctant to form a network of blood vessels that is essential for the distribution of insulin. However, a new tissue-based method is ...
01.06.2018Opportunity to fight drug resistance of bacteria
The resistance of bacteria to antibiotics is constantly increasing, due to which effective treatment is becoming more and more difficult. About 10 years ago, Acinetobacterbaumannii was classified as one of the six most common and severe pathogens. However, the analysis of its genes may generate a breakthrough that has been awaited for by the health ...
09.05.2018New concept for treatment of hemophilia B
CRISPR tool for gene editing will soon become capable of providing hemophilia B patients with help, for it turned out that a transplant of liver cells modified through this method may replace standard injections received by hemophiliac patients.
04.05.2018Evelo seeks to raise USD 100 mln for testing monoclonal microbials on humans
Evelo Bioscience is preparing for subjecting their groundbreaking therapy – relying on microbial strains – to tests conducted on humans. They are to serve the treatment of inflammatory processes and cancer. To this end, the company is planning to obtain USD 100 mln from public investors.
03.04.2018Dark clouds over controversial pesticides
The European Food Safety Authority (EFSA) in Parma has finally determined that neonicotinoids pose a threat to wild bees and honey bee-keeping. However, the decision is being contested by Bayer company – their manufacturer.
19.03.2018Cells as data recorders
The market of recording devices may undergo a significant change in the nearest future. Scientists have used CRISPS-Cas9 – a popular tool for gene-editing – and transformed the DNA of a cell in a way enabling it to record both the duration and sequence of events occuring within the cell.
28.02.2018Groundbreaking veterinary medicine registered by EMA
EMA has authorised the first veterinary medicinal product based on a monoclonal antibody. Cytopoint will be used for the treatment of atopic dermatitis in dogs.
05.01.2018FDA approves unconventional gene therapy
The U.S. Food and Drug Administration (FDA) has just approved a novel gene therapy named Luxturna. It will allow for preventing blindness in those children and adults who suffer from an inherited type of the loss of vision. No similar product to cure a disease of this kind, caused by a mutation within a specific gene, has so far been approved in ...
13.10.2017Living cells to produce ecological plastics
Natural organic compunds that contain fluorine are rarities, as the predominant number of living organisms is not capable of producing them on their own. Despite this, American researchers have managed to genetically modify a microbiological host that began synthetising a monomer for in vivo production of biominerals, allowing for the creation of ...
20.07.2017Stocks of AlderBiopharmaceuticals to lay hold of
AlderBiopharmaceuticals, a pharmaceutical giant, is yet offering its stocks – valued at USD 150 million – for sale again. The funds such acquired are to facilitate both the development of a new medicine for the prevention of migraine and said company’s struggle with large competitors, such as Amgen and Eli Lilly.
05.07.2017Merck climbs to the top of vaccine market
Last year Evaluate company announced that GlaxoSmithKline will have become the leader of vaccine market by year 2022, as directly followed by Sanofi, Pfizer and Merck, in this particular order. Whereas the leader is supposed to remain the same, earlier forecasts pertaining to the other players have already changed.
06.06.2017Tester to analyse genotypes and identify diseases
23andMe company, the producer of commonly available DNA tester, is additionally to inform its customers of the risk of being affected by serious diseases from now on. Such data would previously be not provided to them, and so on account of legal regulations.
26.01.2017The global programme to combat most dangerous epidemics
Recurring outbreaks of such epidemics as SARS, Zika or Ebola virus diseases, as well as their fatal toll, still remind us of our powerlessness. In order to gain the ability to counteract it, a programme aimed at creating supplies of vaccines for the most dangerous epidemic diseases was launched on January 19.
22.01.2017The production of plastics - new tendencies of the 21st century
The 21st century is to pose a lot of challenges for humanity. The imminent depletion of the deposits of crude oil (petroleum) is one of them. It is the major raw material used for the manufacture of polymers, including the so-called "Big Six" category (polyethylene of high and low density, polypropylene, PVC, polystyrene and polyester). ...
15.09.2016The Story of a Certain Takeover: Bayer vs Monsanto - an Update
Everything indicates that Bayer is to take over Monsanto after all - the 14th of September, both companies announced that the agreement would definitely be signed. The negotiations had lasted since the beginning of May.
08.09.2016FDA Banned the Use of 19 Antibacterial Substances in Soaps
Food and Drug Administration (FDA) banned the use of 19 antibacterial substances in soaps. The aforementioned category, in addition to conventional bar soaps, also includes liquid soaps, foam and gel-based hand cleaners, as well as body washes (applied with water). The main reason behind the decision of FDA is the lack of sufficient evidence that ...
17.08.2016Gene Therapy with Money-Return Guarantee
As reported by MIT Technology Review website, the latest gene therapy for children suffering from ADA-SCID will be offered with a money-return guarantee. ADA-SCID is a rare immunological disorder resulting in that the organisms of children are not capable of fighting common infections. Typically, young patients affected die within the first few ...
22.07.2016The Story of a Certain Takeover: Bayer vs Monsanto, Round Two
Recently Bayer placed an official offer to purchase the American tycoon in the market of Life Sciences – Monsanto. The company offered the amount of 62 billion U.S. dollars (USD 122 per stock) to perform the transaction. The resources to execute the takeover would be derived from the issue of stocks and via debt financing. Despite informal talks ...
07.06.2016Profits from innovations in the pharmaceutical industry are decreasing
The pharmaceutical sector is perceived as being among the most innovative ones that allocate the most resources to its development activities. However, as noted in the report released by Deloitte, this activity is becoming less and less profitable. It turns out that the return rate from investments made into pharmaceutical innovations is ...
19.05.2016NIK on Commercialisation of Scientific Research in Poland
Najwyższa Izba Kontroli (NIK), the Supreme Chamber of Control of the Republic of Poland, has assessed the efficiency of support granted to the commercialisation of scientific research in Poland. The subject of evaluation was related to the programmes under the execution of Ministerstwo Nauki i Szkolnictwa Wyższego (MNiSW) – the Ministry of ...
03.03.2016Polish biotechnology in 2014
Graphical overview of polish biotech market in 2014.
16.02.2016Pharmaceutical hits in 2016
Analysts from EvaluatePharma selected drugs currently under review by FDA which have the biggest chance to pay off by 2020. Here we present the summary of top 10.
09.02.2016The best and the worst drugs approved by FDA in 2015
According to BiotechFierce, in 2015 Food and Drug Agency (FDA) approved 45 new drugs. It’s the largest number since 1996. Here we present the summary of Big Pharma companies having last year the highest success with new drug approvals (in terms of potential sales revenue).
29.05.2017An entry to the ASI Managing Register
We hereby would like to inform you that the Management Board of Startit Fund Sp. z o.o. [Ltd.] adopted the resolutions of following numbers on May 26, 2017: 1/5/2017, 2/5/2017 and 3/5/2017. They regard such respective notions as the assignment of Company's previous service activity to its subsidiary, the adoption of Investment Policy of its ...
16.08.2016Meeting Application Received Favourable Opinion under GO_GLOBAL.PL Programme
The National Centre for Research and Development settled the second edition of GO_GLOBAL.PL competition where one of our portfolio companies participated – Meeting Application.
06.06.2016WallStreet conference 2016
Between June 3rd and 5th we have participated in 20th edition of WallStreet conference organized by Stowarzyszenie Inwestorów Indywidualnych (Individual Investors Association), which was held in Gołębiewski hotel in Karpacz. One of the conference partners was our portfolio company Meeting Application.
26.04.2016New investment - Meeting Application Ltd.
We are pleased to announce that the Startit Fund Group has a new member – the Meeting Application Ltd. Company offers the mobile application dedicated to support events like conferences, meetings, fairs and so on. It was created to assist the event leaders on the all stages of the event organizing process by enabling to share with the attendees ...
25.11.2015New company launch - Startit Vet Ltd.
We are pleased to announce, that together with Infini Investment Fund we have launched a new company Startit Vet Ltd. The main goal of the company is to commercialize an intellectual property right concerning new solution for veterinary industry. The project concerns use of chitosan polymer for the treatment and prophylaxis of infections caused by ...
On May 20-21st 2015 we will traditionally participate in BioForum Conference, which is planned to take place in Wroclaw this time. We invite you to visit our stand.
27.03.2015First Cluster World Congress
Between March 24th and 26th in Dabrowa Gornicza First Cluster World Congress took place - the event which is expected to have serious impact on technology transfer process not only in Poland, but also all over the world. During the event, we also had an opportunity to play the role of a panelist and to discuss cooperation of start-ups and investors ...
26.02.2015Conference Innovative Wroclaw
On February 25th 2015, we participated in conference Innovated Wroclaw, which took place at Campus Pracze in Wroclaw Research Center EIT+ Ltd. as part of iLab initiative. Particularly noteworthy was the discussion concerning Design Thinking concept, as effective tool for solving nowadays complex problems, as well as discussion about real obstacles ...
09.01.2015First year of operation
We have left behind us very intense and interesting first year of operation. We are thankful for the trust in us to those of you who already benefited from our services and we invite you to further cooperation. We wish you a successful and happy New Year!
On May 28-29th together with association Bioregion Wielkopolska we have participated in Bioforum 2014. The event traditionally provided unforgettable experience. Thank you for the time that we have spent together.
13.05.2014Conference of General Meeting of a Regional Chamber of Commerce
On May 16th 2014 we will participate in programme conference of General Meeting of a Regional Chamber of Commerce ?Support for enterprenuers in new financial perspective 2014 - 2020? in Katowice. See you there!
09.05.2014Academia Innovation Incubator
We are glad to inform that Startit Fund has been chosen to lead a seed fund "Academia Innovation Incubator - Projects Exchange" that is run by Data Techno Park Ltd. The fund is co-financed by Polish Agency for Enterpreneurship Development from Innovative Economy Operational Programme, Activity no. 3.1.
12.03.2014Pro-Academy Center of Research and Innovation
We are pleased to announce the signing of the agreement with Pro-Academy Center of Research and Innovation as part of system project of Polish Agency for Enterprise Development "NSI of NSS Consultancy for Innovators", implemented under the Operational Program Innovative Economy, priority axis 5 ?Diffussion of Innovation?, Activity 5.2 ...
Starting from February 1st 2014 office of our company is located at Kutnowska Str. 1-3, 53-135 Wroclaw. Welcome!
04.12.2013Meeting with Deputy Prime Minister
On November 29th 2013 we participated in meeting with Deputy Prime Minister, Minister of Economy of Poland Mr. Janusz Piechocinski. The meeting was organized by Lower Silesia Innovation and Science Park. The discussion concerned mainly innovativeness of polish economy in context of new Framework Programme Horizon 2020.
27.11.2013Professional Investor conference
Between 22nd and 24th of November 2013 in Wladyslawowo the latest edition of Professional Investor conference was held. As usual the conference was organized by the Association of Individual Investors, the largest investor organization in our part of Europe. As every year the conference provided unforgettable experience during the numerous lectures ...
Phone: +48 71 725 34 10
ul. E. Kwiatkowskiego 4, 52-326 Wrocław, Poland
© 2019 - Grupa Kapitałowa Startit Fund | All rights reserved.